Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study

Fig. 3

Adjusted cumulative patient survival according to the response to induction therapy (left) and to BVAS (right). Legend: The median survival was 8.4 (7.1–9.6) years in responders vs. 4.7 (2.9–6.8) years in non-responders, p < 0.0001 (left) and 7.5 (6.5–8.6) years in those with BVAS ≤ 15 vs. 6.1 (4.5–7.6) years in those with BVAS > 15, p < 0.0001 (right). BVAS Birmingham vasculitis activity score ver 3

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us